Advertisement
Screener

CURIS, INC. (CRIS) Payments to Acquire Marketable Securities

1.6 / 5 stars · 32/99 Roast Me

CURIS, INC. Payments to Acquire Marketable Securities

CURIS, INC. (CRIS) reported Payments to Acquire Marketable Securities of $93.13 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.

Discontinued › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2022-02-24

  • CURIS, INC. payments to acquire marketable securities for the quarter ending 2019-12-31 was $551.00K, a 7.55% decline year-over-year.
  • CURIS, INC. payments to acquire marketable securities for the quarter ending 2019-09-30 was $2.90M, a 44.43% decline year-over-year.
  • CURIS, INC. payments to acquire marketable securities for the quarter ending 2019-06-30 was $8.02M, a 91.52% increase year-over-year.
  • CURIS, INC. payments to acquire marketable securities for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
  • CURIS, INC. payments to acquire marketable securities for fiscal 2021 was $93.13M, a 74.23% increase from fiscal 2020.
  • CURIS, INC. payments to acquire marketable securities for fiscal 2020 was $53.45M, a 366.19% increase from fiscal 2019.
  • CURIS, INC. payments to acquire marketable securities for fiscal 2019 was $11.46M, a 57.13% decline from fiscal 2018.
  • CURIS, INC. payments to acquire marketable securities for fiscal 2018 was $26.74M, a 47.69% decline from fiscal 2017.
Period endPayments to Acquire Marketable Securities 3 monthPayments to Acquire Marketable Securities 3 month as first filedPayments to Acquire Marketable Securities 6 monthPayments to Acquire Marketable Securities 6 month as first filedPayments to Acquire Marketable Securities 9 monthPayments to Acquire Marketable Securities 9 month as first filedPayments to Acquire Marketable Securities 12 monthPayments to Acquire Marketable Securities 12 month as first filed
2021-12-31$93.13M
10-K · filed 2022-02-24
2020-12-31$53.45M
10-K · filed 2022-02-24
2019-12-31$551.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24
$3.45M
derived: sum of 2 quarters · filed 2022-02-24
$11.46M
derived: sum of 3 quarters · filed 2022-02-24
$11.46M
10-K · filed 2022-02-24
2019-09-30$2.90M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05
$10.91M
derived: sum of 2 quarters · filed 2019-11-05
$10.91M
10-Q · filed 2019-11-05
$11.51M
derived: sum of 4 quarters · filed 2020-03-19
2019-06-30$8.02M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09
$8.02M
10-Q · filed 2019-08-09
$8.61M
derived: sum of 3 quarters · filed 2020-03-19
$13.83M
derived: sum of 4 quarters · filed 2020-03-19
2019-03-31$0.00
10-Q · filed 2019-05-14
$596.00K
derived: sum of 2 quarters · filed 2020-03-19
$5.81M
derived: sum of 3 quarters · filed 2020-03-19
$9.99M
derived: sum of 4 quarters · filed 2020-03-19
2018-12-31$596.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19
$5.81M
derived: sum of 2 quarters · filed 2020-03-19
$9.99M
derived: sum of 3 quarters · filed 2020-03-19
$26.74M
10-K · filed 2020-03-19
2018-09-30$5.21M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05
$9.40M
derived: sum of 2 quarters · filed 2019-11-05
$26.14M
10-Q · filed 2019-11-05
$32.98M
derived: sum of 4 quarters · filed 2019-11-05
2018-06-30$4.19M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09
$20.93M
10-Q · filed 2019-08-09
$27.76M
derived: sum of 3 quarters · filed 2019-08-09
$44.58M
derived: sum of 4 quarters · filed 2019-08-09
2018-03-31$16.75M
10-Q · filed 2019-05-14
$23.58M
derived: sum of 2 quarters · filed 2019-05-14
$40.39M
derived: sum of 3 quarters · filed 2019-05-14
$55.31M
derived: sum of 4 quarters · filed 2019-05-14
2017-12-31$6.83M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26
$23.64M
derived: sum of 2 quarters · filed 2019-03-26
$38.56M
derived: sum of 3 quarters · filed 2019-03-26
$51.12M
10-K · filed 2019-03-26
2017-09-30$16.82M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01
$31.73M
derived: sum of 2 quarters · filed 2018-11-01
$44.29M
10-Q · filed 2018-11-01
$51.45M
derived: sum of 4 quarters · filed 2018-11-01
2017-06-30$14.92M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02
$27.48M
10-Q · filed 2018-08-02
$34.63M
derived: sum of 3 quarters · filed 2018-08-02
$36.37M
derived: sum of 4 quarters · filed 2018-08-02
2017-03-31$12.56M
10-Q · filed 2018-05-03
$19.71M
derived: sum of 2 quarters · filed 2018-05-03
$21.45M
derived: sum of 3 quarters · filed 2018-05-03
$40.73M
derived: sum of 4 quarters · filed 2018-05-03
2016-12-31$7.15M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08
$8.89M
derived: sum of 2 quarters · filed 2018-03-08
$28.17M
derived: sum of 3 quarters · filed 2018-03-08
$57.64M
10-K · filed 2018-03-08
2016-09-30$1.74M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07
$21.02M
derived: sum of 2 quarters · filed 2017-11-07
$50.48M
10-Q · filed 2017-11-07
$78.13M
derived: sum of 4 quarters · filed 2018-03-08
2016-06-30$19.28M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03
$48.74M
10-Q · filed 2017-08-03
$76.39M
derived: sum of 3 quarters · filed 2018-03-08
$105.69M
derived: sum of 4 quarters · filed 2018-03-08
2016-03-31$29.47M
10-Q · filed 2017-05-04
$29.47M
10-Q · filed 2016-05-09
$57.11M
derived: sum of 2 quarters · filed 2018-03-08
$86.41M
derived: sum of 3 quarters · filed 2018-03-08
$95.15M
derived: sum of 4 quarters · filed 2018-03-08
2015-12-31$27.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08
$56.94M
derived: sum of 2 quarters · filed 2018-03-08
$65.68M
derived: sum of 3 quarters · filed 2018-03-08
$123.24M
10-K · filed 2018-03-08
$123.24M
10-K · filed 2016-02-29
2015-09-30$29.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03
$38.03M
derived: sum of 2 quarters · filed 2016-11-03
$95.59M
10-Q · filed 2016-11-03
$95.60M
10-Q · filed 2015-11-09
$98.71M
derived: sum of 4 quarters · filed 2017-03-09
2015-06-30$8.73M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04
$66.30M
10-Q · filed 2016-08-04
$66.30M
10-Q · filed 2015-08-06
$69.41M
derived: sum of 3 quarters · filed 2017-03-09
$82.35M
derived: sum of 4 quarters · filed 2017-03-09
2015-03-31$57.56M
10-Q · filed 2016-05-09
$60.68M
derived: sum of 2 quarters · filed 2017-03-09
$73.61M
derived: sum of 3 quarters · filed 2017-03-09
$85.57M
derived: sum of 4 quarters · filed 2017-03-09
2014-12-31$3.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09
$16.05M
derived: sum of 2 quarters · filed 2017-03-09
$28.01M
derived: sum of 3 quarters · filed 2017-03-09
$41.40M
10-K · filed 2017-03-09
$41.40M
10-K · filed 2015-02-24
2014-09-30$12.94M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09
$24.90M
derived: sum of 2 quarters · filed 2015-11-09
$38.28M
10-Q · filed 2015-11-09
$60.20M
derived: sum of 4 quarters · filed 2016-02-29
2014-06-30$11.96M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06
$25.35M
10-Q · filed 2015-08-06
$47.27M
derived: sum of 3 quarters · filed 2016-02-29
$63.47M
derived: sum of 4 quarters · filed 2016-02-29
2014-03-31$13.39M
10-Q · filed 2015-05-07
$35.31M
derived: sum of 2 quarters · filed 2016-02-29
$51.51M
derived: sum of 3 quarters · filed 2016-02-29
$69.13M
derived: sum of 4 quarters · filed 2016-02-29
2013-12-31$21.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
$38.12M
derived: sum of 2 quarters · filed 2016-02-29
$55.74M
derived: sum of 3 quarters · filed 2016-02-29
$65.83M
10-K · filed 2016-02-29
2013-09-30$16.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10
$33.82M
derived: sum of 2 quarters · filed 2014-11-10
$43.91M
10-Q · filed 2014-11-10
$69.11M
derived: sum of 4 quarters · filed 2015-02-24
2013-06-30$17.62M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
$27.70M
10-Q · filed 2014-08-07
$52.90M
derived: sum of 3 quarters · filed 2015-02-24
$66.69M
derived: sum of 4 quarters · filed 2015-02-24
2013-03-31$10.09M
10-Q · filed 2014-05-09
$35.29M
derived: sum of 2 quarters · filed 2015-02-24
$49.08M
derived: sum of 3 quarters · filed 2015-02-24
$57.50M
derived: sum of 4 quarters · filed 2015-02-24
2012-12-31$25.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24
$38.99M
derived: sum of 2 quarters · filed 2015-02-24
$47.41M
derived: sum of 3 quarters · filed 2015-02-24
$69.15M
10-K · filed 2015-02-24
2012-09-30$13.79M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12
$22.21M
derived: sum of 2 quarters · filed 2013-11-12
$43.96M
10-Q · filed 2013-11-12
$43.21M
10-Q · filed 2012-11-06
$53.86M
derived: sum of 4 quarters · filed 2014-03-13
2012-06-30$8.42M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08
$30.16M
10-Q · filed 2013-08-08
$40.06M
derived: sum of 3 quarters · filed 2014-03-13
$46.69M
derived: sum of 4 quarters · filed 2014-03-13
2012-03-31$21.74M
10-Q · filed 2013-05-09
$31.64M
derived: sum of 2 quarters · filed 2014-03-13
$38.27M
derived: sum of 3 quarters · filed 2014-03-13
$45.01M
derived: sum of 4 quarters · filed 2014-03-13
2011-12-31$9.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-13
$16.53M
derived: sum of 2 quarters · filed 2014-03-13
$23.27M
derived: sum of 3 quarters · filed 2014-03-13
$42.14M
10-K · filed 2014-03-13
2011-09-30$6.63M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06
$13.37M
derived: sum of 2 quarters · filed 2012-11-06
$32.24M
10-Q · filed 2012-11-06
$44.24M
derived: sum of 4 quarters · filed 2013-03-13
2011-06-30$6.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09
$25.61M
10-Q · filed 2012-08-09
$37.61M
derived: sum of 3 quarters · filed 2013-03-13
$56.83M
derived: sum of 4 quarters · filed 2013-03-13
2011-03-31$18.86M
10-Q · filed 2012-05-10
$30.86M
derived: sum of 2 quarters · filed 2013-03-13
$50.09M
derived: sum of 3 quarters · filed 2013-03-13
2010-12-31$12.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-13
$31.22M
derived: sum of 2 quarters · filed 2013-03-13
$65.90M
10-K · filed 2013-03-13
2010-09-30$19.22M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31
$53.90M
10-Q · filed 2011-10-31
2010-06-30$34.67M
10-Q · filed 2011-08-04
2009-12-31$35.83M
10-K · filed 2012-02-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
Silexion Therapeutics Corp (SLXN)$0.001B
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
VivoSim Labs, INC. (VIVS)United States$0.003B
WINDTREE THERAPEUTICS INC /DE/ (WINT)United States$0.003B-0.32
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
AIM ImmunoTech Inc. (AIM)United States$0.006B
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70